Management discusses expert clinical perspectives on CAN-2409 Phase 3 prostate cancer data on a conference call to be held on June 3 at 1 pm. Webcast Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Receives FDA RMAT Designation for CAN-2409
- Candel Therapeutics receives FDA RMAT designation to CAN-2409
- Candel Therapeutics to host investor call on CAN-2409 Phase 3 data
- Candel Therapeutics Unveils Promising Phase 3 Trial Results
- Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue